← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Medosome Biotec, Llc
Alachua, FL
$12,914,262
Total funding
15
Grants
Funding over time
peak $2.8M · FY2015–24$5M$3.8M$2.5M$1.3M$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$12,791,823 · 14
FDA$122,439 · 1
By mechanism
R42$8,959,792 · 4
R44$1,611,097 · 1
R41$1,438,501 · 6
R43$904,872 · 4
Investigators at Medosome Biotec, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Personalized dosing of dichloroacetate for the treatment of rare and common diseases$1,000,000
R42 · FY2020 · HD
A method for accurate and sensitive detection of HIV drug-resistant minority variants$1,000,000
R42 · FY2023 · AI
A method for accurate and sensitive detection of HIV drug-resistant minority variants$999,999
R42 · FY2022 · AI
Prevention of White Matter Injury in Premature Infants$993,274
R42 · FY2020 · HD
Personalized dosing of dichloroacetate for the treatment of rare and common diseases$992,757
R42 · FY2021 · HD
Personalized dosing of dichloroacetate for the treatment of rare and common diseases$985,330
R42 · FY2022 · HD
Next generation quantitative HCV drug resistance assay$834,451
R44 · FY2021 · DK
Personalized dosing of dichloroacetate for the treatment of rare and common diseases$793,897
R42 · FY2017 · HD
Next generation quantitative HCV drug resistance assay$776,646
R44 · FY2022 · DK
Prevention of White Matter Injury in Premature Infants$700,593
R42 · FY2021 · HD
Personalized dosing of dichloroacetate for the treatment of rare and common diseases$695,065
R42 · FY2018 · HD
Metabolism and Mitochondrial Energetics Therapy for Septic Shock$350,000
R42 · FY2024 · GM
Engineering next generation probiotics for delivery of therapeutics$325,000
R43 · FY2023 · TR
Development of Optimized AAV Serotype Vectors for Human Gene Therapy$294,094
R41 · FY2016 · AI
A method for accurate and sensitive detection of HIV drug-resistant minority variants$253,244
R41 · FY2016 · AI
Next generation quantitative HCV drug resistance assay$232,433
R43 · FY2017 · DK
Optimization of recombinant probiotics for oral delivery of ACE2/Ang-(1-7$225,000
R43 · FY2019 · HL
Development of a Novel Therapeutic for Hyperthyroidism$225,000
R41 · FY2019 · DK
Personalized dosing of dichloroacetate for the treatment of rare and common diseases$224,978
R42 · FY2016 · HD
Novel therapies for inherited muscle diseases$224,463
R41 · FY2016 · AR